

2019 – Annual summary

We are now finalising an active year on the Swedish capital markets and would like to thank you for your co-operation during 2019.

During 2019, our newsletters have covered the following topics:

New rules on related party transactions

A summary of the proposed new Swedish legislation that entered into effect on 10 June 2019.

Takeover statistics

The busiest year in the Swedish market in the last decade.

• New rules on remuneration in listed companies

A summary of the new rules for remuneration to senior executives in listed companies that have entered into force as a result of the implementation of the EU Shareholder Rights Directive II.

Preparations for annual general meetings 2020 and trends for companies listed on Nasdaq Stockholm

A summary of dates, action points and recent amendments to be considered when preparing for a listed company's AGM.

The next newsletter will be sent out in January 2020.

Mandates 2019 1(2)



Adviser to Xspray in connection with a directed share issue

2019



Adviser to Nordea and Citigroup on directed share issue in Better Collective

2019



Adviser to Gränges in conjunction with rights issue

2019



Adviser to Lantmännen in connection with issue of subordinated debentures

2019



Adviser to Hembla in connection with Vonovia's mandatory cash offer

2019



Adviser to Samhällsbyggnadsbolaget in connection with its offer for Hemfosa

2019



Adviser to SEB in connection with the issuance of Additional Tier 1 Capital of USD 900 million

2019



Adviser to Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

2019



Adviser to Pandox in connection with a directed share issue of approximately SEK 3 billion

2019



Adviser to Aprea Therapeutics in connection with its listing on Nasdaq New York

2019



Adviser to Samhällsbyggnadsbolaget in connection with its listing on Nasdaq Stockholm

2019




Adviser to Vicore Pharma in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm

2019



Adviser to EQT in connection with the IPO on Nasdaq Stockholm

2019



Adviser to Oncopeptides in connection with a directed share issue in June

2019



Adviser to Equinor in connection with divestment of shares in Lundin Petroleum and investment

2019



Adviser to Calliditas in connection with a directed share issue

2019

Mandates 2019 2(2)

ambea:

Adviser to Ambea on a rights issue 2019

veoneer

Adviser to Veoneer in connection with its USD 600 million capital raise

2019

NUEVOLUTION

Adviser to Nuevolution in connection with the cash offer to the shareholders in Nuevolution by Amgen

2019

ORIFLAME

Adviser to Oriflame in connection with the offer from the af Jochnick family

2019

CREADES

Adviser to Creades on its sale of shares in Lindab

2019

Finan Zero

Adviser to FinanZero in connection with a directed share issue

2019



Adviser to CGI on its offer for Acando

2019




Adviser to Vostok New Ventures Ltd in connection with a split and redemption procedure

2019



Adviser to Cavotec SA in connection with a rights issue

2019



Adviser to Oncopeptides in connection with a directed share issue in January

2019

Contact details

If you have any questions, please contact any of the capital markets lawyers listed below or your regular Vinge contact.

Jesper Schönbeck



Charlotte Levin



D: +46 10 614 33 21
M: +46 70 429 33 21
jesper.schonbeck@vinge.se

D: +46 10 614 31 68
M: +46 70 714 31 68
charlotte.levin@vinge.se

Erik Sjöman

D: +46 10 614 55 77

M: +46 70 624 36 80

erik.sjoman@vinge.se



Dain Hård Nevonen



D: +46 10 614 30 96 M: +46 70 714 30 96 dain.hardnevonen@vinge.se

David Andersson



D: +46 10 614 30 02 M: +46 70 714 30 02 david.andersson@vinge.se



STOCKHOLM GOTHENBURG MALMO HELSINGBORG BRUSSELS

www.vinge.se